Updates in: Hepatitis C Treatment Jocelyn VanOpdorp, PharmD PGY2 Ambulatory Care December 2015

# Learning Objectives

1. Discuss the treatment options for each of the hepatitis C genotypes

2. Identify important considerations to review before using each treatment regimen  $\frac{1}{2}$ 

**3.** Review insurance requirements and preferred treatment regimens

#### Treatment



# Highest Priority

 Advanced fibrosis (Metavir F3) or compensated cirrhosis (Metavir F4)

- 2. Organ transplant
- 3. Type 2/3 mixed cryoglobulinemia with endorgan manifestations
- **4.** Proteinuria, nephrotic syndrome or glomerulonephritis

#### Treatment



# High Priority

1. Fibrosis (Metavir F2)

2. HIV or HBV or other liver co-infection

- 3. Debilitating fatigue
- 4. Type 2 diabetes

5. Porphyria cutanea tarda


## WHY?

#### HALT-C

#### SVR Achieved vs. Not Achieved

Advanced fibrosis from HCV infection

Need for transplant → HR 0.17 (0.06-0.46) Morbidity/mortality → HR 0.15 (0.06-0.38) Hepatocellular carcinoma → HR 0.19 (0.04-0.80)



#### WHY?

#### **Co-Infection**

Accelerates disease progression

**HIV/HCV** → Poor outcomes following transplantation

Increased decompensated liver disease

Higher rate of hepatocellular carcinoma

#### Extrahepatic

#### Cryoglobulinemia

HBV/HCV

Arthralgia Fatigue Purpura

#### **Renal** Disease

Proteinuria Nephrotic syndrome Azotemia

#### Diabetes

Increased insulin resistance Progression to fibrosis and HCC

# **Insurance Requirements**

Sober/Abstaining from drug abuse for a minimum

- Sobriety date


Fibrosis Score:

- F3 or F4
- F0-2 with comorbidity


Liver Biopsy with fibrosis, cirrhosis, vascular changes

Documentation of comorbidities or interactions

#### **Pre-treatment Labs**



## **HCV Medication Targets**



http://www.virology.ws/2010/06/09/a-new-target-for-hepatitis-c-virus/

# Mechanism


NS5B	NS3/4A	NS5A	СҮР ЗА
RNA Polymerase inhibitor	Viral <mark>protease</mark> inhibitor	Replication protein inhibitor	Metabolism inhibitor
Dasa <b>buvir</b>	Parita <b>previr</b>	Ombit <b>asvir</b>	Ritonavir
Sofos <mark>buvir</mark>	Sime <b>previr</b>	Ledip <b>asvir</b>	
		Decleteerin	
		Daclat <b>asvir</b>	

Danovich GM. Handbook of Kidney Transplantation: 5<sup>th</sup> Edition. Wolters Kluwer. 2009. Lippincott Williams and Wilkins.

# **Therapy Considerations**

- 1. Genotype
- 2. Naive/experienced
- 3. Cirrhosis Y/N
- 4. Insurance considerations
- 5. Co-morbid conditions
- 6. Current medications
- 7. Adherence

# **HCV Genotypes**



http://hepcbc.ca/genotypes/

## Treatment Naïve – Genotype 1a

Cirrhosis	Regimen	Length of therapy	n	Efficacy (SVR)
NO	Harvoni *VL <6 million	<b>8</b> * - 12 Weeks	123/1389	98%/98%
	Daklinza/Sovaldi	12 Weeks	71	96%
	Viekira + R	12 Weeks	305	97%
	Olysio/Sovaldi	12 Weeks	155	97%
YES	Harvoni	12 Weeks	138	97%
	Daklinza/Sovaldi +/- R	24 Weeks	34	76% (R)
	Viekira + R	24 Weeks	261	95%
	Olysio/Sovaldi +/- R	24 Weeks	50	88%

## Treatment Naïve – Genotype 1b

Cirrhosis	Regimen	Length of therapy	n	Efficacy (SVR)
NO	Harvoni *VL <6 million	8* - 12 Weeks	123/1389	98%/98%
	Daklinza/Sovaldi	12 Weeks	71	96%
	Viekira	12 Weeks	419	99%
	Olysio/Sovaldi	12 Weeks	155	97%
YES	Harvoni	12 Weeks	138	97%
	Daklinza/Sovaldi +/- R	24 Weeks	34	76% (R)
	Viekira	12 Weeks	60	100%
	Olysio/Sovaldi +/- R	24 Weeks	50	88%

## Treatment Naïve – Genotype 2

Cirrhosis	Regimen	Length of therapy	n	Efficacy (SVR)
NO	Sovaldi + R	12 Weeks	214	94%
	Daklinza/Sovaldi	12 Weeks	26	92%
YES	Sovaldi + R *Includes treatment experienced patients	16 Weeks	109	78%*
	Daklinza/Sovaldi	16 Weeks		

# Treatment Naïve – Genotype 3

Cirrhosis	Regimen	Length of therapy	n	Efficacy (SVR)
NO	Daklinza/Sovaldi	12 Weeks	101	97%
	Sovaldi + R + PEG	12 Weeks	71	96%
	Sovaldi + R	24 Weeks	72	90%
YES	Daklinza/Sovaldi +/- R *European compassionate use	24 Weeks		88%*
	Sovaldi + R + PEG	12 Weeks	23	91%
	Sovaldi + R	24 Weeks	22	82%


## Treatment Naïve – Genotype 4

Cirrhosis	Regimen	Length of therapy	n	Efficacy (SVR)
YES/NO	Harvoni	12 Weeks	42	95%
	Viekira + R	12 Weeks	42	100%
	Sovaldi + R	24 Weeks	38	95%
	Sovaldi + R + PEG	12 Weeks	28	96%

## Treatment Naïve – Genotype 5/6

Cirrhosis	Regimen	Length of therapy	n	Efficacy (SVR)
YES/NO	Harvoni	12 Weeks	41	95%
	Sovaldi + R + PEG	12 Weeks	7	100%

#### **Treatment Naïve Overview**



H = Harvoni D = Daklinza S = Sovaldi V = Viekira Pak R = Ribavirin P = PEG Interferon (R) = Add in specific pts

#### Treatment Experienced – Genotype 1a

Cirrhosis	Regimen	Length of therapy	n	Efficacy (SVR)
NO	Harvoni	12 Weeks	35	94%
	Daklinza/Sovaldi	12 Weeks	96	82-96%
	Viekira + R	12 Weeks	173	96%
	Olysio/Sovaldi	12 Weeks	40	95%
YES -	Harvoni	24 Weeks	77	97%
Compensated	Harvoni + R	12 Weeks	77	96%
	Daklinza/Sovaldi +/- R	24 Weeks	82	82% (R)
	Viekira + R	24 Weeks	98	97%
	Olysio/Sovaldi +/- R *Q80K negative	24 Weeks	38	92%

#### Treatment Experienced – Genotype 1b

Cirrhosis	Regimen	Length of therapy	n	Efficacy (SVR)
NO	Harvoni	12 Weeks	35	94%
	Daklinza/Sovaldi	12 Weeks	96	82-96%
	Viekira	12 Weeks	91	100%
	Olysio/Sovaldi	12 Weeks	40	95%
YES	Harvoni	24 Weeks	77	97%
	Harvoni + R	12 Weeks	77	96%
	Daklinza/Sovaldi +/- R	24 Weeks	82	82% (R)
	Viekira	12 Weeks	60	100%
	Olysio/Sovaldi +/- R *Extrapolated from 1a	24 Weeks	38	92%

#### Treatment Experienced – Genotype 2

Cirrhosis	Regimen	Length of therapy	n	Efficacy (SVR)
YES/NO	Sovaldi + R	16-24 Weeks	32	87-100%
*Fail PEG/R	Sovaldi + R + PEG	12 Weeks	16	94%
YES/NO	Daklinza + Sovaldi +/- R	24 Weeks		
*Fail Sovaldi	Sovaldi + R + PEG	12 Weeks	16	94%

#### Treatment Experienced – Genotype 3

Cirrhosis	Regimen	Length of therapy	n	Efficacy (SVR)
NO	Daklinza/Sovaldi	12 Weeks	7	84%
	Sovaldi + R + PEG	12 Weeks	181	94%
YES	Daklinza/Sovaldi + R	24 Weeks		%
	Sovaldi + R + PEG	12 Weeks	181	82%


#### Treatment Experienced – Genotype 4

Cirrhosis	Regimen	Length of therapy	n	Efficacy (SVR)
YES/NO	Harvoni	12 Weeks	42	95%
	Viekira + R	12 Weeks	41	100%
	Sovaldi + R	24 Weeks	29	87%
	Sovaldi + R + PEG	12 Weeks	28	96%

#### Treatment Experienced – Genotype 5/6

Cirrhosis	Regimen	Length of therapy	n	Efficacy (SVR)
YES/NO	Harvoni	12 Weeks		%
	Sovaldi + R + PEG	12 Weeks	7	100%

#### **Treatment Experienced Overview**



H = Harvoni D = Daklinza S = Sovaldi V = Viekira Pak R = Ribavirin P = PEG Interferon (R) = Add in specific pts

#### Sofosbuvir – Sovaldi

Dosing 400 mg daily Dosage adjustments Not studied in CrCl ≤ 30 mL/min

Administer with or without food

## Sofosbuvir – Sovaldi

Adverse effects:

Fatigue Headache Fever Insomnia Pruritis/rash Nausea Diarrhea Weakness Myalgia

Interactions: Amiodarone

Pgp Inhibitors Ritonavir Cyclosporine Verapamil Azoles

Pgp Inducers: AVOID Antiepileptics Rifampin, St John's Wort

# Simeprevir–Olysio

Dosing 150 mg daily **Dosage** adjustments Not studied in  $CrCl \leq 30 \text{ mL/min}$ **Mutations** NS3 Q80K - Must add ribavirin Administer with food

# Simeprevir – Olysio

#### Adverse effects:

Fatigue Headache Insomnia Pruritis/rash **Photosensitivity** Nausea Diarrhea Myalqia

Interactions: CYP 3A4 Inducers/Inhibitors

Pgp Inducers/Inhibitors and Substrates

Digoxin

Contains sulfa moiety Monitor for signs of hypersensitivity

#### Ledipasvir/Sofosbuvir – Harvoni

Dosing Ledipasvir 90 mg Sofosbuvir 400 mg Dosage adjustments None required May accumulate in  $CrCl \leq 30 \text{ mL/min}$ Administer with or without food,

tablet contains lactose

#### Ledipasvir/Sofosbuvir – Harvoni

Adverse effects:

Fatigue Headache Fever Insomnia Pruritis/rash Nausea Diarrhea Weakness Myalgia

Interactions: Amiodarone Bradycardia Antacids Separate by 4 hours Tenofovir Increased concentration Pgp inhibitors, inducers or substrates PPIs: Max omeprazole 20 mg daily or equivalent

### Daclatasvir – Daklinza

Dosing 60 mg daily Dosage adjustments: CYP 3A4 Strong inhibitors: 30 mg daily Moderate inducers: 90 mg daily Strong inducers: Contraindicated

Administer with or without food

## Daclatasvir – Daklinza

Adverse effects:

Fatigue Headache Fever Insomnia Pruritis/rash Nausea Diarrhea Increased serum lipase

Interactions: Amiodarone

Digoxin Increased concentration

Pgp and 3A4 inhibitors, inducers

Dose adjust or avoid

Pgp and CYP 3A4 substrates

**Increased concentration** 

#### Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir: Viekira Pak

Take

Take with food

AM Dosing PRO: 2 tablets qAM ush down on tablets breaking through back side d: 250 mg BID **Dosage** adjustments Not studied in ESRD Avoid in Child-Pugh class B/C

Administer with food

Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir: Viekira Pak

Adverse effects:

Fatigue Headache Fever Insomnia

**Pruritis/dermatitis** 

Nausea/Diarrhea

Myalgia

**Decreased Hgb** 

**Increased bili/ALT** 

Interactions: **Estrogen products** Digoxin Increased concentration Pgp and 3A4 inhibitors, inducers, substrates **MANY** interactions HIV co-infection Avoid protease

inhibitors

### Ribavirin

Dosing: -Weight-based <75 kg: 1000 mg daily ≥75 kg: 1200 mg daily -Daily in 2 divided doses WITH food

## Ribavirin

#### Adverse effects:

- Hemolytic Anemia
- Fatigue Headache/Insomnia
- Alopecia
- Nausea/Anorexia
- Myalgia/Arthralgia
- Flu-like Symptoms Bilirubin elevation

Pearls:

- Oral
  - Tablet
  - Capsule
  - Solution

#### **Interactions:** PEG or NRTI increase AE

Dose adjust for:

- Renal dysfunction
- Toxicity

# **Insurance Considerations**

Insurance Type	Insurance Provider	Preferred Regimen	Notes	
Medicaid	Passport	Harvoni	*Recent switch from Viekira F2 now covered	
	Coventry	Harvoni		
	Wellcare	Harvoni		
	Humana	Harvoni	*3 monthly negative tox screens	
Private	Express Scripts	Viekira Pak		
	CVS Caremark	Harvoni		
	Envision Rx	Harvoni		
	Aetna	Harvoni		
	Optimum Rx	Harvoni		

#### Target Conditions and Med Rec

**HIV/HBV** Co-infection

**Cardiovascular** Disease

GERD/PUD

## HIV/HBV Co-Infection

#### NRTI

Tenofovir (TDF only) Caution with Harvoni

#### NNRTI


Efavirenz Etravirine Nevirapine

Avoid with Olysio, Viekira Increase Daklinza dose

#### PI

Ritonavir ANY boosted PI Avoid with Viekira, Olysio Decrease Daklinza dose

### **Cardiovascular** Disease



## **HIV Co-Infection**

#### GERD/PUD

Proton Pump Inhibitors Unless = 20mg omeprazole

Therapeutically equivalent PPI doses<sup>a</sup>

Avoid with Harvoni

PPI	Low dose (mg/d)	Standard dose (mg/d)
Esomeprazole	20	40
Lansoprazole	15	30
Omeprazole	10-20	20-40
Pantoprazole	20	40
Rabeprazole	10	20

# Target Medications – 3A4, Pgp

#### **Inducers**

Antiepileptics -Phenytoin -Phenobarbital -Carbamazepine

Anti-infectives -Rifampin

Herbals - St. Johns Wort

#### **Inhibitors**

Anti-infectives -HIV protease inhibitors -Erythromycin -Azole antifungals Cardiovascular -Diltiazem -Verapamil -Amiodarone Herbals

- Grapefruit

# Target Medications – Pgp/3A4

<u>**PGP/3A4 Interactions</u>** *HMG-COA Reductase Inhibitors* Statins</u>

*Moderate Inducers* Efavirenz Etravirine Dexamethasone Modafinil

Substrates Fluticasone Inhaled/Nasal Steroids Daklinza, Viekira

Daklinza, Viekira, Olysio

Viekira

### Adherence

Every pill, every day, at about the same time!

Harvoni: 1 pill once daily Daklinza/Sovaldi: 2 pills once daily Viekira Pak: 3 pills qAM, 1 pill qHS

**Ribavirin: Always BID with FOOD** 

## **Treatment Timeline**

Initial workup: Up to 1-2 months

Start	Week 2	Week 4/5	Week 12/13	Week 24	Week 36
	CBC Riba only	CBC CMP HCV VL	CBC CMP HCV VL	CBC CMP HCV VL	CBC CMP HCV VL
		MD Visit	MD Visit	MD Visit	MD Visit

Danovich GM. Handbook of Kidney Transplantation: 5<sup>th</sup> Edition. Wolters Kluwer. 2009. Lippincott Williams and Wilkins.

## **Recap of Process**

**Treatment Steps** 

- **1.** Clean + Sober >6 months
- **2.** Baseline Labs/MD visit
- 3. Full Medication Reconciliation
- 4. Initial PA for medication
- 5. Appeal Process
- 6. Follow Up
- 7. HCC Review

Updates in: Hepatitis C Treatment Jocelyn VanOpdorp, PharmD PGY2 Ambulatory Care December 2015